Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European Journal of Cancer

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejca.2015.11.007PMID 26796600
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma.

  2015cited by this paper
• Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma

  2015cited by this paper
• Stability of PCR targets for monitoring minimal residual disease in neuroblastoma.

  2012cited by this paper
• Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors

  2012cited by this paper
• Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma

  2011cited by this paper
• Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

  2011cited by this paper
• Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.

  2011cited by this paper
• Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma

  2011cited by this paper
• The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma.

  2011cited by this paper
• Accumulation of segmental alterations determines progression in neuroblastoma.

  2010cited by this paper
• The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

  2009cited by this paper
• Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.

  2009cited by this paper
• Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells

  2009cited by this paper
• The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.

  2009cited by this paper
• Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

  2009cited by this paper
• Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.

  2009cited by this paper
• Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers

  2008cited by this paper
• Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma

  2008cited by this paper
• PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.

  2008cited by this paper
• Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97.

  2008cited by this paper
• Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting

  2007cited by this paper
• Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol.

  2006cited by this paper
• Standardization of the Immunocytochemical Detection of Neuroblastoma Cells in Bone Marrow

  2005influential reference
• Concentration of circulating rhodopsin mRNA in diabetic retinopathy.

  2004cited by this paper
• Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines.

  2001cited by this paper
• Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma.

  2000cited by this paper
• Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers.

  1998cited by this paper
• Biology and genetics of human neuroblastomas.

  1997cited by this paper
• Infant Cancer in the U.S.: Histology‐Specific Incidence and Trends, 1973 to 1992

  1997cited by this paper
• Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive?

  1997cited by this paper
• International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review.

  1996cited by this paper
• Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.

  1996cited by this paper
• The recurrence patterns of stages I, II and III neuroblastoma: experience with 77 relapsing patients.

  1996cited by this paper
• Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma.

  1995cited by this paper
• Metastatic neuroblastoma—Does combining several “magic bullets” make a difference?

  1995cited by this paper
• Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study.

  1991cited by this paper
• Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy.

  1989cited by this paper
• International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.

  1988cited by this paper
• International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma.

  1988cited by this paper
• Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

  1984cited by this paper
• Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma.

  1984cited by this paper
• Factors influencing survival of children with nonmetastatic neuroblastoma

  1976cited by this paper

• GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025

  2025cites this paper
• Evaluating Bone Marrow Involvement in Pediatric Neuroblastoma: Traditional Methods and Emerging Technologies—A Systematic Review

  2025cites this paper
• Sensitive liquid biopsy monitoring correlates with outcome in the prospective international GPOH-DCOG high-risk neuroblastoma RT-qPCR validation study

  2024cites this paper
• A comprehensive overview of liquid biopsy applications in pediatric solid tumors

  2024cites this paper
• Distinct Expression Profiles of Neuroblastoma-Associated mRNAs in Peripheral Blood and Bone Marrow of Non-High-Risk and High-Risk Neuroblastoma Patients

  2024cites this paper
• RT-PCR demonstrates superior sensitivity and specificity in detecting the five neuroblastoma genes compared to the flow cytometry method for measurable residual disease

  2023cites this paper
• Predictors of Survival after Resection of Children with Neuroblastoma

  2022cites this paper
• The Diagnostic Value of 18F-FDG PET/CT Bone Marrow Uptake Pattern in Detecting Bone Marrow Involvement in Pediatric Neuroblastoma Patients

  2022cites this paper
• Flow cytometry of bone marrow aspirates from neuroblastoma patients is a highly sensitive technique for quantification of low-level neuroblastoma

  2021cites this paper
• The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review

  2020cites this paper
• Clinical characteristics and prognosis of 40 patients with periorbital metastasis of neuroblastoma

  2020cites this paper
• Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma

  2019cites this paper
• Dynamics of Minimal Residual Disease in Neuroblastoma Patients

  2019cites this paper
• Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR

  2018cites this paper
• Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis

  2017cites this paper
• The effects of selective inhibitors of N-Glycosylation and Endoplasmic Reticulum stress inducers on Neuroblastoma cell proliferation and Apoptosis

  2017cites this paper
• PCR-based amplification of circulating RNAs as prognostic and predictive biomarkers – Focus on neuroblastoma☆

  2016cites this paper